Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

About 75% of all breast cancers are hormone receptor-positive (HR+). However, the efficacy of endocrine therapy is limited due to the high rate of either pre-existing or acquired resistance. In this work we reconstructed the pathways around estrogen receptor (ER), mTOR, and cyclin D in order to comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Occhipinti, Giulia, Romagnoli, Emanuela, Santoni, Matteo, Cimadamore, Alessia, Sorgentoni, Giulia, Cecati, Monia, Giulietti, Matteo, Battelli, Nicola, Maccioni, Alessandro, Storti, Nadia, Cheng, Liang, Principato, Giovanni, Montironi, Rodolfo, Piva, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174681/
https://www.ncbi.nlm.nih.gov/pubmed/32351542
http://dx.doi.org/10.3389/fgene.2020.00349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174681/
https://www.ncbi.nlm.nih.gov/pubmed/32351542
http://dx.doi.org/10.3389/fgene.2020.00349

Ejemplares similares